Talimogene Laherparepvec
Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy derived from a modified herpes simplex virus type 1, engineered to selectively replicate in and destroy tumor cells while also expressing GM-CSF to stimulate systemic anti-tumor immunity. It is approved for intralesional treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions, and is being investigated for other solid tumors including bladder and breast cancers. Its dual mechanism of direct oncolysis and immune activation makes it a unique cancer therapeutic.
Therapeutic Areas
Pharmacokinetics (PK)
Pharmacodynamics (PD)
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy derived from a modified herpes simplex virus type 1, engineered to selectively replicate in and destroy tumor cells while also expressing GM-CSF to stimulate systemic anti-tumor immunity. It is approved for intralesional treatment of unresectable cutaneous, subcutaneous, and nodal melanoma lesions, and is being investigated for other solid tumors including bladder and breast cancers. Its dual mechanism of direct oncolysis and immune activation makes it a unique cancer therapeutic.
Yes, Talimogene Laherparepvec is an approved drug. It has reached clinical phase 4. It is classified as a Gene.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108727. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="talimogene-laherparepvec"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/talimogene-laherparepvec/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/talimogene-laherparepvec/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/talimogene-laherparepvec/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="talimogene-laherparepvec"></drugfyi-drug>